Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Carcinoma, Non-Small Cell Lung: early-phase trial registry
43 of 133 indexed Carcinoma, Non-Small Cell Lung trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #86 of 28,707 conditions by registered trial count.
133 US clinical trials · 43 currently recruiting · #86 of 28,707 conditions by registered trial count
Carcinoma, Non-Small Cell Lung: 133 US clinical trials tracked, 43 recruiting.
Carcinoma, Non-Small Cell Lung is the subject of 133 registered US clinical trials on ClinicalTrials.gov, 43 of them currently open to new participants. 27 are in Phase 3-4 (later-stage) and 92 in Phase 1-2 (earlier-stage). The most active sponsor is Pfizer, running 14 of these trials.
Enrollment posture brief
Registry condition carcinoma-non-small-cell-lung
OPEN 43 | RECR 32% | LATE 27 | EARLY 92 | RANK #86 | SPON 14
Volume-matched condition peers
Nearest open-share peer: Anatomic Stage IIIB Breast Cancer AJCC v8 (32% recruiting · 34 trials)
Carcinoma, Non-Small Cell Lung lists 43 open slots (32% of 133 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Carcinoma, Non-Small Cell Lung on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Carcinoma, Non-Small Cell Lung is recruiting below its size-band peers.
43 of 133 indexed trials (32.3%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Carcinoma, Non-Small Cell Lung trials is spread across many organizations.
Pfizer accounts for 14 of 133 trials (10.5%). 59 distinct sponsors appear on at least one study for this condition label.
-
Typical Carcinoma, Non-Small Cell Lung enrolment sits around 126 participants.
Median target enrolment is 126 among the 131 trials that report a genuine target (sentinel values excluded). 58 of those (44.3%) plan for fewer than 100 participants.
-
Carcinoma, Non-Small Cell Lung research is mostly interventional.
123 interventional and 10 observational studies make up this index (92.5% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
133 total, page 2 of 3
Study of Pembrolizumab (MK-3475) Monotherapy Versus Sacituzumab Govitecan in Combination With Pembrolizumab for Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-3475-D46)
Merck Sharp & Dohme
NCT05609968
Study of Pembrolizumab/Vibostolimab (MK-7684A) in Combination With Concurrent Chemoradiotherapy Followed by Pembrolizumab/Vibostolimab Versus Concurrent Chemoradiotherapy Followed by Durvalumab in Participants With Stage III Non-small Cell Lung Cancer (MK-7684A-006)
Merck Sharp & Dohme
NCT05298423
A Study of Neoadjuvant Chemotherapy Plus Nivolumab Versus Neoadjuvant Chemotherapy Plus Placebo, Followed by Surgical Removal and Adjuvant Treatment With Nivolumab or Placebo for Participants With Surgically Removable Early Stage Non-small Cell Lung Cancer
Bristol-Myers Squibb
NCT04025879
Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid Tumors
Seagen, a wholly owned subsidiary of Pfizer
NCT03485209
Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation
Novartis Pharmaceuticals
NCT04699188
A Study of TAK-788 in Adults With Non-Small Cell Lung Cancer
Takeda
NCT02716116
A Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared With Carboplatin-Pemetrexed, in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Characterized by Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions
Janssen Research & Development
NCT04538664
A Study Of Lorlatinib Versus Crizotinib In First Line Treatment Of Patients With ALK-Positive NSCLC
Pfizer
NCT03052608
A Study Comparing Adjuvant Alectinib Versus Adjuvant Platinum-Based Chemotherapy in Patients With ALK Positive Non-Small Cell Lung Cancer
Hoffmann-La Roche
NCT03456076
Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations
Seagen, a wholly owned subsidiary of Pfizer
NCT04579380
A Study of Repotrectinib Versus Crizotinib in Participants With Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naïve ROS1-positive Non-Small Cell Lung Cancer (NSCLC) (TRIDENT-3)
Bristol-Myers Squibb
NCT06140836
A Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC)
Eli Lilly and Company
NCT04819100
A Study to Assess the Safety and Efficacy of AZD7789 in Participants With Advanced or Metastatic Solid Cancer
AstraZeneca
NCT04931654
A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers
Novartis Pharmaceuticals
NCT05544929
A Study of Disitamab Vedotin in Previously Treated Solid Tumors That Express HER2
Seagen, a wholly owned subsidiary of Pfizer
NCT06003231
Study of Safety and Efficacy of DKY709 Alone or in Combination With PDR001 in Patients With Advanced Solid Tumors.
Novartis Pharmaceuticals
NCT03891953
NT-I7 in Combination With Atezolizumab in Previously Untreated, PD-L1-expressing, Locally Advanced or Metastatic NSCLC
NeoImmuneTech
NCT04984811
Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation
Novartis Pharmaceuticals
NCT05358249
A Study of Combination Therapy With Amivantamab and Cetrelimab in Participants With Metastatic Non-small Cell Lung Cancer
Janssen Research & Development
NCT05908734
A Study of LOXO-260 in Cancer Patients With a Change in a Particular Gene (RET) That Has Not Responded to Treatment
Eli Lilly and Company
NCT05241834
Premedication to Reduce Amivantamab Associated Infusion Related Reactions
Janssen Research & Development
NCT05663866
A Study of PF-08046052/SGN-EGFRd2 in Advanced Solid Tumors
Seagen, a wholly owned subsidiary of Pfizer
NCT05983133
A Study of Amivantamab and Capmatinib Combination Therapy in Unresectable Metastatic Non-small Cell Lung Cancer
Janssen Research & Development
NCT05488314
A Phase 2 Study Adding Ascorbate to Chemotherapy and Radiation Therapy for NSCLC
Joseph J. Cullen, MD, FACS
NCT02905591
Oleclumab (MEDI9447) Epidermal Growth Factor Receptor Mutant (EGFRm) Non-small Cell Lung Cancer (NSCLC) Novel Combination Study
MedImmune
NCT03381274
A Study to Learn About the Study Medicine PF-07985045 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Change in a Gene.
Pfizer
NCT06704724
A Study of SGN-MesoC2 in Advanced Solid Tumors
Seagen, a wholly owned subsidiary of Pfizer
NCT06466187
Astra Zeneca (Immuno Stereotactic Ablative Body Radiotherapy) ISABR Study: Randomized Phase I/II Study of Stereotactic Body Radiotherapy
Jonsson Comprehensive Cancer Center
NCT03148327
MK-3475 and Gemcitabine in Non-Small Cell Lung Cancer (NSCLC)
Providence Health & Services
NCT02422381
A Study of Combination Therapy With Amivantamab and Docetaxel in Participants With Metastatic Non-small Cell Lung Cancer
Janssen Research & Development
NCT06532032
A Clinical Trial of PF-08046037 Alone or With Sasanlimab in Patients With Advanced or Metastatic Malignancies
Pfizer
NCT06974734
Safety & Efficacy of Consolidative Hypofractionated Radiation Therapy for Boosting Residual Lung Cancer With Durvalumab
University of Nebraska
NCT04748419
Metabolic Response to Food in Lung Cancer
Pennington Biomedical Research Center
NCT05937074
A Study In Patients With Non-Small Cell Lung Cancer To Test If Erlotinib Plus SU011248 Is Better Than Erlotinib Alone
Pfizer
NCT00457392
Evaluation of FKB238 and Avastin in Patients With Advanced/Recurrent Non-squamous Non-small Cell Lung Cancer
Centus Biotherapeutics Limited
NCT02810457
Lume Lung 2 : BIBF 1120 Plus Pemetrexed Compared to Placebo Plus Pemetrexed in 2nd Line Nonsquamous NSCLC
Boehringer Ingelheim
NCT00806819
Study of Pembrolizumab Given With Ipilimumab or Placebo in Participants With Untreated Metastatic Non-Small Cell Lung Cancer (NSCLC) (MK-3475-598/KEYNOTE-598)
Merck Sharp & Dohme
NCT03302234
Study of Neurologic Progression With Motexafin Gadolinium and Radiation Therapy (SMART)
Pharmacyclics
NCT00054795
A Study of Preferences for the First-Line Treatment of Advanced/Metastatic Non-Small Cell Lung Cancer
Bristol-Myers Squibb
NCT05250817
Study of Oral cMET Inhibitor INC280 in Patients With EGFR Wild-type (wt), Advanced Non-small Cell Lung Cancer (NSCLC) (Geometry Mono-1)
Novartis Pharmaceuticals
NCT02414139
Real World Data on Gi(l)Otrif® Dose Adjustment
Boehringer Ingelheim
NCT02751879
A Study Of PF-05082566 As A Single Agent And In Combination With Rituximab
Pfizer
NCT01307267
Evaluation Of The Efficacy Of The Combination Of Axitinib With Pemetrexed And Cisplatin In The Treatment Of Non-Squamous Non-Small Cell Lung Cancer
Pfizer
NCT00768755
This Study is to Compare the Efficacy of ZD6474 and ZD1839 in Subjects With NSCLC.
Genzyme, a Sanofi Company
NCT00059722
A Phase 1 Study in Participants With Advanced Cancer
Eli Lilly and Company
NCT01115790
Study to Evaluate Erlotinib With or Without SNDX-275 (Entinostat) in the Treatment of Patients With Advanced NSCLC
Syndax Pharmaceuticals
NCT00602030
An Exploratory Pharmacogenomic Study of Monotherapy Erbitux in Subjects With Metastatic Non Small Cell Lung Carcinoma
Eli Lilly and Company
NCT00207116
Study Of SU011248 In Patients With Metastatic Non-Small Cell Lung Cancer
Pfizer
NCT00092001
Phase III Study to Determine the Efficacy of Durvalumab in Combination With Chemotherapy in Completely Resected Stage II-III Non-small Cell Lung Cancer (NSCLC)
AstraZeneca
NCT04385368
Study of DN101 and Taxotere in Patients With Advanced Non-Small Cell Lung Cancer
Novacea
NCT00066885
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 58 |
| Phase 2 | 34 |
| Phase 3 | 27 |
Top Sponsors
Named interventions
Most-linked intervention names on Carcinoma, Non-Small Cell Lung records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Carcinoma, Non-Small Cell Lung trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Carcinoma, Non-Small Cell Lung page
133 registered trials, 43 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 43 Carcinoma, Non-Small Cell Lung trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Pfizer sponsors the most Carcinoma, Non-Small Cell Lung trials on record, review their full trial history before evaluating a specific study. See Pfizer's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Carcinoma, Non-Small Cell Lung condition card totals 133 registered trials; most-linked intervention Carboplatin; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.